Other Information.
−Removed: On November 10, 2022, we entered into amendments to the employment agreements (the “Employment Agreement Amendments”) with our Chief Executive Officer, Ankit Mahadevia, M.D., and Chief Financial Officer, Satyavrat Shukla, which amend certain provisions of their prior employment agreements with the Company (the “Prior Employment Agreements,”
−Removed: and together with the Employment Agreement Amendments, the “Amended Employment Agreements”).
−Removed: The Employment Agreement Amendments amend the Prior Employment Agreements to, inter alia, increase the benefits provided to Dr.
−Removed: Mahadevia and Mr.
−Removed: Shukla in the event that following a Change of Control (as defined in the Amended Employment Agreements), their employment with us is terminated by us without Cause or by Dr.
−Removed: Mahadevia or Mr.
−Removed: Shukla for Good Reason (in each case, as defined in the Amended Employment Agreements) (a “Qualified Change of Control Termination”).
−Removed: Under the Amended Employment Agreements, in the event of a Qualified Change of Control Termination, with respect to cash compensation, (i) Dr.
−Removed: Mahadevia will receive 18 months of his then-current base salary plus the amount of his then-current target performance bonus, and (ii) Mr.
−Removed: Shukla will receive 12 months of his then-current base salary plus the amount of his then-current target performance bonus.
−Removed: The foregoing description of the Employment Agreement Amendments is a summary only and is qualified in its entirety by reference to the Employment Agreement Amendments, which are attached hereto as Exhibit 10.6 and 10.7, respectively, and are incorporated herein by reference.
Exhibit Description
2 unchanged sentences
Form or Schedule
−Removed: Amendment 1 to Consulting Agreement, dated August 4, 2022, by and between the Registrant and Cristina Larkin
−Removed: Spero Therapeutics, Inc.
−Removed: 2017 Stock Incentive Plan, as amended
−Removed: (Exhibit 10.1)
−Removed: License Agreement, dated September 21, 2022, by and between the Registrant and GlaxoSmithKline Intellectual Property (No.
−Removed: Share Purchase Agreement, dated September 21, 2022, by and between the Registrant and Glaxo Group Limited
−Removed: Employment Agreement, dated August 11, 2022, by and between the Registrant and Kamal Hamed
−Removed: Amendment to Employment Agreement, dated November 10, 2022, by and between the Registrant and Ankit Mahadevia, M.D.
−Removed: Amendment to Employment Agreement, dated November 10, 2022, by and between the Registrant and Satyavrat Shukla
−Removed: Amendment to Employment Agreement, dated November 10, 2022, by and between the Registrant and Kamal Hamed, M.D., M.P.H., M.B.A
−Removed: Amendment to Employment Agreement, dated November 10, 2022, by and between the Registrant and Timothy Keutzer
−Removed: Amendment to Employment Agreement, dated November 10, 2022, by and between the Registrant and Tamara Joseph
+Added: Second Amendment to Employment Agreement, dated as of February 1, 2023, by and between the Registrant and Timothy Keutzer
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
10 unchanged sentences
#+ Management contract or compensatory plan.
−Removed: Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (“[***]”) because the identified confidential portions (i) are not material and (ii) is the type that the Registrant treats as private or confidential.
* The certification attached as Exhibit 32 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Spero Therapeutics, Inc.
2 unchanged sentences
SPERO THERAPEUTICS, INC.
−Removed: November 14, 2022
/s/ Ankit Mahadevia, M.D.
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 14, 2022
/s/ Satyavrat Shukla
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.